The role of backward mutations on the within-host dynamics of HIV-1

Journal of Mathematical Biology

Volumn 67, Issue 5, 2013, Pages 1111-1139

  Kitayimbwa, John M ^a   Mugisha, Joseph Y T ^a   Saenz, Roberto A ^b,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b ETH ZURICH   (Switzerland)

^c UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

Drug resistance; HIV 1; Virus mutations; Within host model

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; VIROLOGY;

ANTI-HIV AGENTS; BASIC REPRODUCTION NUMBER; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, GENETIC; MUTATION;

EID: 84885372653     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-012-0581-2     Document Type: Article

References (38)

1. Boffito M, Winston A, Owen A (2005) Host determinants of antiretroviral activity. Curr Opin Infect Dis 18(6): 543-549.
2. Bonhoeffer S, Nowak MA (1997) Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Roy Soc B 264(1382): 631-637.
3. Buckley RM, Gluckman SJ (2002) HIV infection in primary care. W. B. Saunders Company, An imprint of Elsevier Science, Philadelphia.
4. Burkle WS (2002) Antiretroviral therapy for HIV: drug resistance and sequencing. J Assoc Nurses AIDS Care 13(1): 76-80.
5. Carr J (1981) Applications of centre manifold theory. Springer, New York.
6. Castillo-Chávez C, Song BJ (2004) Dynamical models of tuberculosis and their applications. Math Biosci Eng 1: 361-404.
7. 0 and its role on global stability., Mathematical approaches for emerging and reemerging infectious diseases: an introduction. IMA, Minneapolis.
8. Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362(9400): 2002-2011.
9. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellman NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001) Virological and immunological consequences of discontinuing combinational antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
10. Eron JJ, Benoit SL, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200500 CD4+ cells per cubic millimeter. N Engl J Med 333: 1662-1669.
11. Frost SDW, Nijhuis M, Schuurman R, Boucher CAB, Brown Leigh AJ (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74(14): 6262-6268.
12. Gonzalez RG, Cheng LL, Westmoreland SV, Sakaie KE, Becerra LR, Lee PL, Masliah E, Lackner AA (2000) Early brain injury in the SIV-macaque model of AIDS. AIDS 14: 2841-2849.
13. Hecht FM, Grant RM (2005) Resistance testing in drug-naïve HIV-infected patients: is it time? Clin Infect Dis 41: 1324-1325.
14. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE (2002) A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16: 2175-2182.
15. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203: 1174-1181.
16. Kane BM (2008) DRUGS, the straight facts: HIV/AIDS treatment drugs. Chelsea House Publishers, Philadelphia.
17. Kepler TB, Perelson AS (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci 95: 11514-11519.
18. Kuritzkes DR (2004) Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs 18(5): 259-273.
19. Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
20. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69(8): 5087-5094.
21. Markowitz M, Louie M, Hurley A, Sun E, Mascio MD, Perelson AS, Ho DD (2003) A novel antiviral intervention results in more accurate assessment of human immunodeciency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037-5038.
22. McLean AR, Nowak MA (1992) Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 6: 71-79.
23. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD (1998) Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279: 1223-1227.
24. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, London.
25. Nowak MA, Bonhoeffer S, Shaw GM, May RM (1997) Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 184: 203-217.
26. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000) Adherence to protease inhibitor therapy an outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
27. Perelson AS (2002) Modeling viral and immune system dynamics. Nature 2: 28-36.
28. Perelson AS, Kirschner DE, De Boer R (1993) Dynamics of HIV infection of CD4+ lymphocytes in vivo. Math Biosci 114: 81-125.
29. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
30. Perelson AS, Essunger P, Ho DD (1997) Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 11: S17-S24.
31. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782-1785.
32. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci 97: 7681-7686.
33. Rong L, Feng Z, Perelson AS (2007) Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 247: 804-818.
34. UNAIDS (2009) Report on the global AIDS epidemic. http://data. unaids. org/pub/Report/2009/JC1700_Epi_Update_2009_en. pdf.
35. Vaidya NK, Rong L, Marconi VC, Kuritzkes DR, Deeks SG, Perelson AS (2010) Treatment mediated alterations in HIV preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol 6(11): e1001012. doi: 10. 1371/journal. pcbi. 1001012.
36. van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci 180: 29-48.
37. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279: 1977-1983.
38. Weber J, Rangel HR, Meyer PR, Chakraborty B, Tadele M, Martinez MA, Martinez-Picado J, Marotta ML, Mirza M, Ruiz L, Clotet B, Wrin T, Petropoulos CJ, Quinones-Mateu ME (2003) A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeciency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol 84: 2217-2228.